ENDRA Life Sciences (NDRA) Tops Q3 EPS by 1c; Reports Cash and Cash Equivalents of $11.8M

ENDRA Life Sciences (NASDAQ: NDRA) reported Q3 EPS of ($0.06), $0.01 better than the analyst estimate of ($0.07).

For earnings history and earnings-related data on ENDRA Life Sciences (NDRA) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• SOS Limited signs non-binding memo for Indonesia data center project